Castor Oil: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Castor Oil, so there is currently no new predicted indication. The drug’s own recorded uses are listed below; no uses are recorded for this drug in the available data.
Quick overview
Item
Content
New predicted indications
None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug
0
Evidence level
Not applicable
Australia Market Status
Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items
1 (valid: 1)
Known uses recorded for this drug
Approved (supported by a licence or label)
Indication
Source
none
none
Related to an approved indication (same disease category)
Indication
Approved category
none
none
Relations recorded in the knowledge graph (no approval found)
Indication
none
Australia Market Information
Licence
Product
Dosage form
Status
328G
nan
nan
Valid
Safety Considerations
Drug Interactions: 100 potential interactions were identified in the interaction database, and the 20 retrieved were all rated Moderate. Examples include abiraterone, tramadol, acetazolamide, hydrocortisone, salbutamol, hydrochlorothiazide, amiloride, amiodarone, amisulpride, propofol, arsenic trioxide, lumefantrine and azithromycin. Many of these involve QT-prolonging or electrolyte-affecting drugs, so any systemic use (for example, as a laxative with potassium-depleting effects) would need specific review.
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.